Systemic disorders of connective tissue. Systemic involvement of connective tissue, unspecified
Conditions
Interventions
Intervention 1: Intervention group 1: 40 mg triamcinolon hexaactenoid once injected into the knee joint. Intervention 2: Intervention group 2: 8 mg dexamethason once injected into the knee joint.
Treatment - Drugs
Intervention group 1: 40 mg triamcinolon hexaactenoid once injected into the knee joint
Intervention group 2: 8 mg dexamethason once injected into the knee joint
Sponsors
Vice Chancellor for Research of Tabriz University of Medical Sciences, Connective Tissue Diseases
Eligibility
Sex/Gender
All
Age
20 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Rheumatoid arthritis based on ACR-EULAR 2010 criteria; had one or both knee swelling Exclusion Criteria: joint or adjacent tissue infection; Non inflammatory arthritis on joint fluid analysis; Crystal related arthritis; Joint injection in previous 6 months; patients that need to change their drugs
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Knee swelling. Timepoint: Weeks 1 and 3. Method of measurement: Observation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Knee circumference. Timepoint: Weeks 1 and 3. Method of measurement: Physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir ghorbanihaghjo
Tabriz university of medical sciences
Outcome results
None listed